GeneDx Holdings Corp. (WGS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
GeneDx: Time To Buy The Dip
GeneDx's recent 50% stock drop post-Q1 earnings is seen as an overreaction, despite a projected modest growth slowdown from 42% to 30-35%. The company is expanding product lines, improving margins, and increasing insurance coverage, with the recent acquisition of Fabric Genomics offering growth and cost synergies. GeneDx's valuation is attractive compared to peers, with a forward P/E of 30 and projected profitability next year, unlike Natera and Tempus AI.
GeneDx Holdings Corp. (WGS) Q1 Earnings and Revenues Surpass Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.33 per share a year ago.
GENEDX HOLDINGS (WGS) Upgraded to Buy: Here's Why
GENEDX HOLDINGS (WGS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GeneDx: Strengthening Leadership In Genomic Diagnostics
GeneDx Holdings Corp. leverages genomic sequencing and data science for early diagnosis and treatment, focusing on pediatric outpatient and neonatal ICU settings. GeneDx will report Q1 2025 earnings on April 30, with expectations for continued revenue growth and margin improvement. Expanding market opportunity by leveraging data set expertise across more disease applications, new patient access channels, adult diagnostics, and international markets.
Will Robust Exome and Genome Growth Boost WGS' Q1 Earnings Results?
GeneDx is expected to have continued the strong 2024 momentum across all metrics in the first quarter of 2025.
GeneDx Holdings: There Is Upside Potential, But Price Tag Is Rich
GeneDx Holdings Corp. is delivering strong revenue growth, but it is still burning cash, which makes me hesitant. At 7x sales, WGS stock feels expensive, given its current financials. If GeneDx can prove it can generate sustainable free cash flow, I'd reconsider my stance.
GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know
GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Reviewing GeneDx Holdings: Exome Testing And EPIC Aura Integration Make It A GARP 'Buy'
GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and reducing healthcare costs. WGS basically targets a $45 billion genetic testing market with growth in pediatric, NICU, and adult segments via EPIC Aura integration.
GeneDx CEO on pediatric genetic testing, future of genome sequencing and share surge
Katherine Stueland, GeneDx CEO, joins 'Closing Bell' to discuss company earnings and the future of genome sequencing.
GeneDx Holdings Corp. (WGS) Q4 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q4 2024 Results Conference Call February 18, 2025 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen William Bonello - Craig-Hallum Capital Group Matt Stanton - Jefferies Matt Sykes - Goldman Sachs Mark Massaro - BTIG Brandon Couillard - Wells Fargo Operator Good day, and thank you for standing by. Welcome to the GeneDx Fourth Quarter 2024 Earnings Conference Call.
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Surpass Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.59 per share a year ago.
GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play
A little-known stock started to make a huge name for itself in 2024. That stock is GeneDX NASDAQ: WGS.
